Biocryst Pharmaceuticals (BCRX) Free Cash Flow Growth (3y) (2013 - 2026)
Biocryst Pharmaceuticals (BCRX) Free Cash Flow Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.77 Bn | 35.04 Bn | 1.97 Bn | 9.86% |
| 2 | Zoetis | 34.11 Bn | 32.16 Bn | 1.62 Bn | -18.92% |
| 3 | United Therapeutics | 23.68 Bn | 21.53 Bn | 648.10 Mn | 2.82% |
| 4 | Aurora Cannabis | 16.48 Bn | 16.40 Bn | 33.43 Mn | - |
| 5 | Neurocrine Biosciences | 16.19 Bn | 14.88 Bn | 800.70 Mn | 45.60% |
| 6 | Elanco Animal Health | 11.44 Bn | 11.01 Bn | 785.00 Mn | 39.19% |
| 7 | Alkermes | 7.28 Bn | 6.77 Bn | -116.06 Mn | -82.02% |
| 8 | Lantheus Holdings | 6.48 Bn | 5.98 Bn | 230.92 Mn | 18.94% |
| 9 | Hims & Hers Health | 6.35 Bn | 5.60 Bn | 396.79 Mn | 114.21% |
| 10 | Biocryst Pharmaceuticals | 1.99 Bn | 1.75 Bn | 151.04 Mn | -9.39% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -9.39% |
| Dec 31, 2025 | 141.14% |
| Sep 30, 2025 | 48.24% |
| Jun 30, 2025 | 50.91% |
| Mar 31, 2025 | 29.40% |
| Dec 31, 2024 | 44.02% |
| Sep 30, 2024 | 32.57% |
| Jun 30, 2024 | 64.91% |
| Mar 31, 2024 | 4.09% |
| Dec 31, 2023 | 44.48% |
| Sep 30, 2023 | 18.39% |
| Jun 30, 2023 | 14.74% |
| Mar 31, 2023 | -26.78% |
| Dec 31, 2022 | -32.29% |
| Sep 30, 2022 | -5.57% |
| Jun 30, 2022 | -4.43% |
| Mar 31, 2022 | -42.39% |
| Dec 31, 2021 | -11.69% |
| Sep 30, 2021 | 12.32% |
| Jun 30, 2021 | -23.03% |